生物疗法和小分子在性直肠炎的结果:比利时多中心队列研究
Pauline Lemmens1, Edouard Louis2, Wouter Van Moerkercke3
1Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.
概括
先进的疗法显示了性直肠炎 (UP) 的有效性和安全性,这是一个经常被排除在试验之外的条件. 维多利祖马布在这个患者群体中表现出优越的药物持久性.
科学领域:
- 胃肠病学和肝病学
- 临床药理学 临床药理学
- 炎症性肠道疾病研究研究
背景情况:
- 先进的疗法 (生物制剂,小分子) 已被批准用于中度至重度的性结肠炎.
- 临床试验往往不包括患有隔离性直肠炎的患者,从而为这一特定人群创造了证据差距.
- 性直肠炎 (UP) 的特点是直肠炎症的长度高达15厘米.
研究的目的:
- 评估先进疗法在被诊断为性直肠炎 (UP) 的患者中的疗效和安全性.
- 在UP患者中评估短期无类固醇临床缓解,药物持续性和生存结果 (无复发,无切除术).
- 为了确定影响UP患者接受先进疗法的治疗成功的因素.
主要方法:
- 一个多中心的回顾性队列研究,对167名连续患者进行了积极的UP.
- 患者在常规治疗失败后开始先进治疗.
- 主要终点:无类固醇的临床缓解. 二级终点:药物持续性,没有复发的存活率,没有切除术的存活率. 统计分析包括后勤和考克斯回归.
主要成果:
- 36.3%的治疗疗程实现了短期无类固醇临床缓解.
- 缓解更常见于生物素朴的患者,接受韦多利祖马布治疗的患者,中度内镜活动的患者和较低的BMI (<25 kg/m2) 的患者.
- 维多利祖马布和较短的疾病持续时间与药物持续时间显著增加有关. 没有发现新的安全信号.
结论:
- 先进的疗法是有效和安全的治疗性直肠炎 (直肠局限性性结肠炎).
- 应考虑将UP患者纳入未来先进疗法的随机对照试验.
- 维多利祖马布在改善UP患者药物耐药性方面表现有前途.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
175
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
175
Inflammatory Bowel Disease IV: Pharmacological Management
154
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
154
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
505
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
505
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
461
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
461
Drugs for Treatment of Diarrhea-Predominant IBS
217
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
217
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
357
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
357


